Baylor College of Medicine: Leukemia trials

The registry lists 12 Leukemia studies with Baylor College of Medicine as lead sponsor. 1 are open to participants now and 3 have results posted.

Phase 1 9Phase 2 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)RecruitingNCT06345027Phase 1
• Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)TerminatedNCT00579111Phase 1/2Results posted
• Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHDCompletedNCT00539695Phase 2Results posted
• T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell GraftsCompletedNCT00368355Phase 2Results posted
• Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALLActive, not recruitingNCT00881920Phase 1
• Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor CellsCompletedNCT00458679Phase 1
• Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor CellsWithdrawnNCT00224354Phase 1
• Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor CellsCompletedNCT00078520Phase 1
• Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CMLTerminatedNCT00069992Phase 2
• Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor VaccineCompletedNCT00058799Phase 1
• Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor CellsCompletedNCT00058786Phase 1
• Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell TransplantationCompletedNCT00057005Phase 1